Sera Prognostics (SERA) Set to Post Earnings on Wednesday

Sera Prognostics (NASDAQ:SERA) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.14) per share and revenue of $0.07 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.07 million. On average, analysts expect Sera Prognostics to post ($0.62) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

Sera Prognostics Stock Up 0.9%

Shares of Sera Prognostics stock traded up $0.02 on Wednesday, reaching $2.07. The company’s stock had a trading volume of 248 shares, compared to its average volume of 44,034. Sera Prognostics has a 52 week low of $1.56 and a 52 week high of $3.85. The firm’s fifty day simple moving average is $2.05 and its two-hundred day simple moving average is $2.17. The company has a market capitalization of $81.62 million, a price-to-earnings ratio of -3.09 and a beta of 1.06.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Sera Prognostics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Insider Transactions at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 20,139 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $2.00, for a total transaction of $40,278.00. Following the completion of the sale, the chief executive officer directly owned 844,870 shares in the company, valued at $1,689,740. The trade was a 2.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 39,661 shares of company stock valued at $79,563 over the last 90 days. Company insiders own 11.30% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a women’s health diagnostics company focused on improving pregnancy outcomes through biomarker-based testing. The company uses proteomics, bioinformatics and clinical data to develop diagnostic and prognostic products designed to identify risks associated with pregnancy complications.

Its lead product is the PreTRM test, a blood-based test intended to assess a pregnant woman’s risk of spontaneous preterm birth in a singleton pregnancy. The test measures specific protein biomarkers and is designed to provide physicians with information that may support risk assessment, patient management and care planning during pregnancy.

Founded in 2008 and headquartered in Salt Lake City, Utah, Sera Prognostics primarily serves the U.S.